Table 1.
Comparison of patient baseline characteristics between everolimus-based therapy and chemotherapy.
| Baseline characteristics1 | Everolimus-based therapy | Chemotherapy | P value† |
|---|---|---|---|
| N = 234 | N = 137 | ||
| Age (years) | |||
| Median (range) | 64.0 (41.0, 89.0) | 62.0 (38.0, 81.0) | 0.050∗ |
| Race/ethnicity, n (%) | |||
| White | 150 (64.1) | 69 (50.4) | 0.009∗ |
| Non-white | 84 (35.9) | 68 (49.6) | |
| Insurance plan type, n (%) | |||
| Commercial/private insurance | 133 (56.8) | 80 (58.4) | 0.466 |
| Medicare only | 81 (34.6) | 50 (36.5) | |
| Others | 20 (8.5) | 7 (5.1) | |
| Index therapy line | |||
| First line | 84 (35.9) | 69 (50.4) | 0.014∗ |
| Second line | 61 (26.1) | 33 (24.1) | |
| Third line and above | 89 (38.0) | 35 (25.5) | |
| Adjusted CCI1 | |||
| Median (range) | 0.0 (0.0, 5.0) | 0.0 (0.0, 8.0) | 0.172 |
| Sites of metastatic disease, n (%) | |||
| Bone | 150 (64.1) | 77 (56.2) | 0.132 |
| Liver | 82 (35.0) | 71 (51.8) | 0.002∗ |
| Lung | 92 (39.3) | 84 (61.3) | <0.001* |
| Visceral metastases | 148 (63.2) | 116 (84.7) | <0.001∗ |
| Number of metastatic sites, n (%) | |||
| 1 | 111 (47.4) | 24 (17.5) | <0.001∗ |
| 2 | 79 (33.8) | 53 (38.7) | |
| 3 | 36 (15.4) | 47 (34.3) | |
| 4 | 8 (3.4) | 12 (8.8) | |
| 5 | 0 (0.0) | 1 (0.7) | |
| Physician assessed tumor volume | |||
| High | 18 (7.7) | 29 (21.2) | <0.001∗ |
| Medium | 132 (56.4) | 92 (67.2) | |
| Low | 84 (35.9) | 16 (11.7) | |
| ECOG performance status | |||
| 0—Asymptomatic | 65 (27.8) | 34 (24.8) | 0.655 |
| 1—Symptomatic but completely ambulatory | 100 (42.7) | 68 (49.6) | |
| 2—Symptomatic, <50% in bed during the day | 27 (11.5) | 12 (8.8) | |
| 3—Symptomatic, >50% in bed, but not bedbound | 4 (1.7) | 1 (0.7) | |
| Not recorded in medical record | 38 (16.2) | 22 (16.1) | |
| Prior chemotherapy in mBC setting | 52 (22.2) | 23 (16.8) | 0.209 |
| Disease status | |||
| Recurrent patients with adjuvant ET, n (%) | 148 (63.2) | 106 (77.4) | 0.008∗ |
| Recurrent patients without adjuvant ET, n (%) | 37 (15.8) | 9 (6.6) | |
| De novo, n (%) | 49 (20.9) | 22 (16.1) | |
| Months from initiation of last adjuvant endocrine therapy to the first stage IV mBC diagnosis | |||
| Median (range) | 17.9 (0.0, 149.6) | 14.2 (0.0, 163.7) | 0.458 |
†Statistical comparisons were conducted using Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. ∗ P < 0.05.
Notes:
1The adjusted CCI calculated the comorbidity index excluding metastatic breast cancer (score of 6).